Kornimate/medical-research-clean huggingface dataset:
prone position during ecmo in severe acute respiratory syndrome coronavirus 2 (sars-cov-2) hypoxaemic patient

Conditions: SARS CoV 2 Infection; Hypoxemic Respiratory Failure

Summary: introduction: the main manifestation of covid-19 pneumonia is acute respiratory distress syndrome (ards), which in some cases can be more severe than intubation, extracorporeal membrane venous oxygenation (vv-ecmo) to ensure hematosis. despite support from vv-ecmo, some patients may remain hypoxemic. one possible therapeutic procedure for these patients is the application of the prone position. objective: the main aim of this study was to investigate the modification of the pao2/fio2 ratio, the compliance of the respiratory system in vv-ecmo with refractory hypoxemia. the secondary objective was to evaluate the safety and feasibility of the inclined position for ecmo. methods: the investigators reviewed the electronic records and lists of all 23 covid-19 patients. were placed for the first time in pp with an average duration of 16 h . patient characteristics, pre-ecmo characteristics, ventilator/ecmo settings, and changes in ventilator/ecmo settings and blood gas analysis before and after pp.

the main objective of the current study was to investigate the change in pao2/fio2 ratio, the compliance of the respiratory system in vv-ecmo patients with persistent hypoxemia. measurements were taken before pp, 1 h after the start of the pp, at the end of the pp cycle. the secondary objective of this study was to assess the safety and feasibility of emergency positioning for patients with severe ards during ecmo treatment.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of sars cov 2 infection complicated by ards, and needed a vv ecmo. * patient who presented refractory hypoxemia during vv ecmo. exclusion criteria: * patient who has received ecmo v-a or ecmo vv for reasons other than ards.

Keywords: ecmo ards prone position covid compliance
pet dynamics to response-adapted neoadjuvant therapy in tnbc

Conditions: Triple Negative Breast Cancer

Summary: eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. a pet scan will be performed at baseline and after 1 cycle of therapy. a breast mri will be performed after treatment completion. patients with complete clinical response will proceed to surgery. patients with clinical residual disease will complete neoadjuvant rescue with 4 cycles of doxorubicin/cyclophosphamide prior to surgery. if residual disease identified after surgery, adjuvant therapy to be determined by the treating oncologist (may include doxorubicin/cyclophosphamide/pembrolizumab, capecitabine etc).

eligible participants will undergo baseline procedures including research bloodwork, mri and pet scan. participants will then be treated with one cycle of paclitaxel, carboplatin and pembrolizumab (tcarbo/pembro). at the end of cycle one patients will undergo repeat procedures (bloodwork and pet scan), and then continue with treatment for an additional three cycles. ctdna will be collected on day 1 of each cycle. at the end of treatment patients will undergo repeat mri. patients achieving a clinical complete response (cr) on mri will proceed with surgery. patients with clinical residual disease (rd) on mri will be recommended a biopsy, and be recommended "rescue" neoadjuvant doxorubicin and cyclophosphamide with pembrolizumab (ac/pembro) for four additional cycles, and then proceed with surgery. note: patients/treating physician may opt to proceed with surgery. archival tissue will be collected from the surgical product. patients achieving a pathologic cr (pcr) may proceed with adjuvant pembrolizumab per standard of care, and treating physician's discretion. patients with pathological rd may proceed with "rescue" adjuvant ac/pembrolizumab for four additional cycles (if not given neoadjuvantly), per treating physician discretion. the participants may also receive aadjuvant capecitabine or olaparib as indicated and per treating physician's discretion.

Eligibility criteria:
inclusion criteria: 1. stage ii-iii tnbc - estrogen receptor (er) and progesterone receptor (pr) up to and including 10% is eligible 2. age ≥ 18 years 3. eastern cooperative oncology group (ecog) performance status of 0 to 2 4. eligible for standard chemo-immunotherapy as determined by treating physician, including consideration of: 1. adequate marrow and organ function 2. co-morbid conditions do not preclude the use of chemo-immunotherapy (such as uncontrolled autoimmune disease, or the use of immunosuppressive medications) 5. patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study exclusion criteria: 1. patients unable to undergo pet or mri 2. evidence of metastatic disease or loco-regional recurrence (i.e. distant or chest wall recurrence) 3. inflammatory breast cancer 4. previous treatment with paclitaxel, carboplatin, or immune checkpoint inhibitors

Keywords: breast cancer triple negative neoadjuvant
assessment of the minimal residual disease in ovarian cancer from circulating tumor dna and immune repertoire

Conditions: Ovarian Cancer

Summary: to analyze the proportion of hereditary tumors in ovarian cancer patients in china, as well as the spectrum of variations; the ctdna characteristics in patients with ovarian cancer; the correlation between the clonal status of mutations and therapy response; whether ctdna detection can be used to predict the risk of ovarian cancer recurrence; and the characteristics of immune repertoire before and after treatment in patients with ovarian cancer.

100 oc cases with available matched tumor dna and plasma will be collected. all patients will be treated according to clinical guidelines, and receive circulating tumor dna (ctdna) liquid biopsy at the time of diagnosis, at mid treatment, at the end of treatment and during follow-up. the study will be ended when the patients have progressive disease (pd) or reach the longest follow-up time (2 years).

Eligibility criteria:
inclusion criteria: * patients who have not received treatment including radiotherapy, chemotherapy, and surgery. * expected to achieve satisfactory tumor cytoreductive surgery. * estimated lifetime is more than 3 months. * understand the research plan and voluntarily participate in the study, sign the informed consent form. * ability to collect specimens from each time point and provide corresponding clinical information. exclusion criteria: * patients who will receive new adjuvant therapy. * patients who have other primary cancer. * pregnant or breast-feeding woman. * patients with severe mental illness. * patients achieve unsatisfactory tumor cytoreductive surgery. * patients who voluntarily withdraw for any reason. * patients who cannot complete the research plan.
ultra-low tidal volume mechanical ventilation in ards through ecmo

Conditions: ARDS

Summary: primary research question for the full ultimate randomized clinical trial (rct): what is the effect of ultra-protective ventilation facilitated by extracorporeal membrane oxygenation (ecmo) versus best current conventional ventilation (cv) on all-cause hospital mortality among patients with early moderate-severe acute respiratory distress syndrome (ards)? secondary research questions: among patients with early moderate-severe ards, what is the effect of ultra-protective ventilation versus cv on: (1) duration of mechanical ventilation; (2) duration of icu and hospital stay; (3) organ dysfunction; (4) barotrauma; and (5) mortality at other time-points (icu discharge, 28-day, 60-day)? the ultimate pilot study: before embarking on a definitive multinational trial to address the questions listed above, the ultimate pilot study has these 3 specific feasibility objectives: 1. to assess adherence to our explicit mechanical ventilation protocols, with particular focus on delivered tidal volumes in both groups; 2. to estimate the rate of patient recruitment and understand barriers to recruitment; and 3. to measure and understand the reasons for crossovers or rescue by ecmo in the control group. in addition, we will monitor safety issues, recording serious adverse events in both groups.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. endotracheal mechanical ventilation for ≤ 5 days 3. early moderate-severe ards (berlin definition) - all of the following conditions for ≤ 48 hours i. pao2/fio2 ≤200 with peep \> 5 cmh2o ii. bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules iii. respiratory failure not fully explained by cardiac failure or fluid overload iv. within one week of a known insult of new or worsening respiratory symptoms 4. ards severity criterion - either 1 of: 1. pao2/fio2 ≤ 150 mm hg, on peep ≥ 10 cm h2o and fio2 ≥ 0.5 exclusion criteria: 1. currently receiving any form of ecmo (e.g., venovenous, venoarterial, or hybrid configuration) 2. chronic hypercapnic respiratory failure defined as paco2 \> 60 mmhg in the outpatient setting 3. home mechanical ventilation (non-invasive ventilation or via tracheotomy), not cpap 4. actual body weight exceeding 1 kg per centimeter of height 5. severe hypoxemia with pao2/fio2 \< 80 mmhg 6. expected mechanical ventilation duration \< 48 hours 7. treating team is in the process of moving to a palliative mode of care 8. moribund patient not expected to survive 24 hours despite ongoing life-sustaining therapies 9. confirmed diffuse alveolar hemorrhage from vasculitis 10. contraindications to limited anticoagulation (e.g., active gi bleeding, bleeding diathesis) 11. pregnancy - due to unknown effects of paco2 changes on placental blood flow

Keywords: ecmo mechanical ventilation ventilator-induced lung injury
pilon fracture reduction and functional outcome

Conditions: Pilon Fracture of Tibia

Summary: this prospective case series will essentially examine the influence of reduction quality on the primary functional outcome (as assessed using the faam) of patients with pilon fractures treated with plate fixation. the plates used in this trial can be chosen according to the preferences of the surgeon.

a prospective case series to examine the influence of reduction quality on the primary functional outcome (as assessed using the faam) of patients with pilon fractures treated with plate fixation. radiological parameters including single/combined alignment and various articular measurements will also be validated according to their reliability. the sensitivity of the effects of reduction quality on functional outcome, and an extended evaluation of patient-rated functional and social outcomes as well as their outcome expectations will also be assessed as part of the secondary study aims.

Eligibility criteria:
inclusion criteria: * age 18 years and older * patients with a unilateral intraarticular pilon fracture of the distal tibia classified according to ao: ao 43 - b1, b2 and b3 (partial intraarticular) ao 43 - c1, c2 and c3 (total intraarticular) * definitive fracture fixation with a plate within 4 weeks after accident (temporary fixation with an external fixator, cast or traction is allowed) * signed written informed consent (by the patients) and agreement to attend the planned fu evaluations exclusion criteria: * contralateral fracture of the distal half of the tibia/fibula/talus * pathologic fracture * severe polytrauma: injury severity score (iss) \> 28 * preexisting severe vascular disease (chronic venous insufficiency, chronic arterial occlusive disease) * drug or alcohol abuse * american society of anesthesiologists (asa) class v and vi * inability to walk independently prior to injury event * neurological and psychiatric disorders that would preclude reliable assessment

Keywords: tibial fractures pilon pilon fractures tibial plafond reduction quality anatomical reduction functional outcome ankle joint
bryostatin 1 and cisplatin in treating patients with metastatic or unresectable stomach cancer

Conditions: Stage III Gastric Cancer; Stage IV Gastric Cancer

Summary: phase ii trial to study the effectiveness of bryostatin 1 and cisplatin in treating patients who have metastatic or unresectable stomach cancer. drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. bryostatin 1 may increase the effectiveness of cisplatin by making tumor cells more sensitive to the drug. combining cisplatin with bryostatin 1 may kill more tumor cells.

objectives: i. determine the response rate and survival in patients with metastatic or unresectable carcinoma of the stomach treated with bryostatin 1 and cisplatin. ii. determine the toxic effects of this regimen in these patients. iii. determine the molecular determinants of response to this regimen in these patients. outline: this is a multicenter study. patients receive bryostatin 1 iv over 72 hours on days 1-3 followed by cisplatin iv over 1 hour on day 4. treatment repeats every 3 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria: * diagnosis of metastatic or unresectable carcinoma of the stomach * measurable disease * no brain metastasis * performance status - karnofsky 70-100% * more than 3 months * wbc at least 3,000/mm\^3 * platelet count at least 100,000/mm\^3 * hemoglobin at least 10 g/dl * no history of any bleeding disorders * bilirubin no greater than 1.5 mg/dl * transaminases no greater than 2 times normal * creatinine no greater than 1.5 mg/dl * creatinine clearance at least 60 ml/min * no history of peptic ulceration or gastrointestinal bleeding * no active infection * no seizure disorder * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * hiv negative * no other serious concurrent illness that would preclude study entry * no medical, social, or psychological factors that would preclude study entry * no prior chemotherapy * no prior radiotherapy * more than 4 weeks since prior major surgery * prior incomplete resection allowed * no other prior antitumor treatment
tumor molecular profiling in patients with prostate cancer

Conditions: Prostate Cancer; Metastatic Prostate Adenocarcinoma

Summary: the aim of the study was to evaluate the prevalence, the prognostic and predictive value of gene alterations in unselected patients with prostate cancer. patients with histologically confirmed prostate cancer, treated at hellenic cooperative oncology group (hecog)-affiliated departments, were included. the presence of gene alterations was assessed using the foresentia® prostate panel developed by nipd genetic.

data on tumor molecular profiling of european patients with prostate cancer is limited. the aim of the study was to evaluate the prevalence, the prognostic and predictive value of gene alterations in unselected patients with prostate cancer. patients with histologically confirmed prostate cancer, treated at hellenic cooperative oncology group (hecog)-affiliated departments, were included. the presence of gene alterations was assessed using the foresentia® prostate panel developed by nipd genetic. the primary endpoint was the prevalence of gene alterations in homologous recombination repair (hrr) genes. secondary endpoint was overall survival.

Eligibility criteria:
inclusion criteria: metastatic prostate cancer recurrent prostate cancer locally advanced prostate cancer high-risk operable prostate cancer available ffpe tumor tissue exclusion criteria: absence of tumor tissue available for analysis lack of informed consent lack of clinicopathological data

Keywords: tumor molecular profiling mutations homologous recombination repair brca2 prognostic
safety and tolerability of irx-101 in patients receiving intravitreal injections

Conditions: Retinal Disease

Summary: this is a randomized, double-masked study to evaluate the tolerability and safety of irx-101 versus 5% povidone-iodine (pi) in subjects receiving intravitreal anti-vegf injections.


Eligibility criteria:
inclusion criteria: 1. capable of giving informed consent 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. male or female, ≥ 18 years of age and receiving intravitreal anti-vegf injections in one or both eyes exclusion criteria: 1. current or past diagnosis of endophthalmitis 2. current diagnosis of uveitis 3. monocular patients (vision 20/100 or worse in one eye) who are receiving injections in the better seeing eye 4. current use of viscous lidocaine products for ocular anesthesia prior to ivt 5. currently receiving intravitreal steroid injections 6. concurrent participation in another clinical trial 7. females who are pregnant, planning to become pregnant or lactating
acute effects of high-intensity interval training with mindfulness-based recovery on executive function in children

Conditions: Healthy Volunteers

Summary: the goal of this randomized cross-over trial is to learn about the effect of a single bout of 20-min mindfulness-based high-intensity interval training (mf-hiit), mf-only, and hiit-only in relative to sitting rest on executive function (ef) in 10-12 years old children. the main question it aims to answer are: question 1: whether a single bout of 20-min mf-hiit has larger beneficial effect on ef performance than that following a 20-min session of mf-only and hiit-only in relative to the sitting rest question 2: whether a single bout of 20-min mf-hiit has a larger beneficial effect on brain functioning, as measured by the n2 and p3 components of event-related potential (er) during ef performance than that following a 20-min session of mf-only and hiit-only in relative to the sitting rest participants will visit the laboratory on 5 separate days (\> 2-day washout between days) in which they have not previously participated in structured physical activities. participants will complete the testing and/or receive treatments below: day 1: * kaufman brief intelligence test (kbit) to assess intelligence quotient * treadmill-based exercise test to measure cardiorespiratory fitness (maximum oxygen consumption) days 2-5 * each day, participants will complete each of the four intervention conditions (mf-hiit, mf-only, hiit-only, sitting) * participants' heart rate and self-reported affect and rating of physical exertion will be measured * participants will complete a modified flanker task and a task-switching task to assess inhibitory control and cognitive flexibility * participants will wear an eeg cap to measure the n2 and p3 components of the event-related potential during the inhibitory control and cognitive flexibility performance researcher will compare the cognitive outcome measures following the mf-hiit, mf-only, and hiit-only conditions with the sitting condition to see if mf and hiit has beneficial effects on children's ef. further, researcher will compare the cognitive outcome measures following the mf-hiit compared with mf-only and hiit-only conditions to see if combining mf with hiit has greater beneficial effects on children's ef than mf and hiit alone.


Eligibility criteria:
inclusion criteria: * age between 10-12 years old * intelligence quotient ≥ 85 * capable of performing exercise based on pre-participation health screening * no formal diagnosis of cognitive disorders (e.g., attention deficit hyperactivity disorder) and neurological diseases (e.g., epilepsy) exclusion criteria: * age outside of the range of 10-12 years old * intelligence quotient \< 85 * no capable of performing exercise based on pre-participation health screening * has formal diagnosis of cognitive disorders (e.g., attention deficit hyperactivity disorder) and neurological diseases (e.g., epilepsy)

Keywords: interval exercise mindfulness executive function brain function children
action observation training for upper limb rehabilitation in stroke patients

Conditions: Stroke Rehabilitation

Summary: the purpose of this study is to assess the changes in physiological parameters and clinical scales resulting from treatment with aot (action observation training) in subjects with subacute stroke. furthermore, this study assess the perception of applicability and satisfaction degree for this kind of treatments.

after being informed about the study, all patients give written informed consent and will undergo a 1-week screening period to determine eligibility for study entry. patient who meet the eligibility requirements will be given clinical and instrumental assessments before the start of treatment (t0) after 3 weeks (t1), at the end of the treatment (t2) and after 6 months (t3). a training program of 4 weeks including 250 videos of every day actions has been developed. videos includes transitive and intransitive actions. each week has a five day program, each day is divided in three sessions, in each session there are observation and imitation and attentional questions. aot is always performed in conjunction with the conventional rehabilitation program.

Eligibility criteria:
inclusion criteria: * should had experienced first ever ischemic or haemorrhagic stroke * fugl-meyer assessment \< 55 * normal or corrected to normal visual acuity exclusion criteria: * presence of severe neuropsychological disorders * medical conditions likely to interfere with the ability to safely complete the study protocol * pain in the upper limb assessed with the visual analogue scale (vas)\> 7 * intracranial metal implants * history of seizures or epilepsy * severe cardiopulmonary, renal, and hepatic diseases * pregnancy

Keywords: stroke rehabilitation aot kinematic brain plasticity mirror neuron system
evaluation of the performance of different daily disposable lens designs in habitual soft contact lens wearers

Conditions: Myopia

Summary: the main objective of the study is to refit existing soft lens wearers with two different daily disposable contact lens types, lens a and lens b, to determine their performance after one week of wear.

this study is a prospective, bilateral eye, double-masked, randomized, 1-week cross-over, daily-wear design involving two different daily disposable lens types. each lens type will be worn for approximately one week, during which participants record their subjective lens-wear experience.

Eligibility criteria:
inclusion criteria: 1. is at least 18 years of age and has full legal capacity to volunteer; 2. has read and signed an information consent letter; 3. self reports having a full eye examination in the previous two years; 4. anticipates being able to wear the study lenses for at least 8 hours a day, 7 days a week; 5. is willing and able to follow instructions and maintain the appointment schedule; 6. habitually wears soft contact lenses, for the past 3 months minimum; 7. has refractive astigmatism no higher than -0.75dc in each eye; 8. can be fit and achieve binocular distance vision of at least 20/30 snellen (available lens parameters are sphere -1.00 to -6.00d, 0.25d steps). exclusion criteria: 1. is participating in any concurrent clinical or research study; 2. habitually wears one of the study contact lenses; 3. has any known active\* ocular disease and/or infection that contraindicates contact lens wear; 4. has a systemic condition that in the opinion of the investigator may affect a study outcome variable; 5. is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable; 6. has known sensitivity to the diagnostic sodium fluorescein used in the study; 7. self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment; 8. has undergone refractive error surgery or intraocular surgery.